<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
      <PMID Version="1">35593080</PMID>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>20</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1878-0261</ISSN>
          <JournalIssue CitedMedium="Internet">
            <PubDate>
              <Year>2022</Year>
              <Month>May</Month>
              <Day>20</Day>
            </PubDate>
          </JournalIssue>
          <Title>Molecular oncology</Title>
          <ISOAbbreviation>Mol Oncol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Altered splicing of ATG16-L1 mediates acquired resistance to tyrosine kinase inhibitors of EGFR by blocking autophagy in non-small cell lung cancer.</ArticleTitle>
        <ELocationID EIdType="doi" ValidYN="Y">10.1002/1878-0261.13229</ELocationID>
        <Abstract>
          <AbstractText>Despite the initial efficacy of using tyrosine kinase inhibitors of epidermal growth factor receptor (EGFR-TKIs) for treating patients with non-small cell lung cancer (NSCLC), resistance inevitably develops. Recent studies highlight a link between alternative splicing and cancer drug response. Therefore, we aimed to identify deregulated splicing events that play a role in resistance to EGFR-TKI. By using RNA sequencing, reverse transcription PCR (RT-PCR) and RNA interference, we showed that overexpression of a splice variant of the autophagic gene ATG16-L1 that retains exon 8 and encodes the β-isoform of autophagy-related protein 16-1 (ATG16-L1-β) concurs acquired resistance to EGFR-TKI in NSCLC cells. Using matched biopsies, we found increased levels of ATG16-L1-β at the time of progression in 3 of 11 NSCLC patients treated with EGFR-TKI. Mechanistically, gefitinib-induced autophagy was impaired in resistant cells that accumulated ATG16-L1-β. Neutralization of ATG16-L1-β restored autophagy in response to gefitinib, induced apoptosis and inhibited the growth of in ovo tumor xenografts. Conversely, overexpression of ATG16-L1-β in parental sensitive cells prevented gefitinib-induced autophagy and increased cell survival. These results support a role for defective autophagy in acquired resistance to EGFR-TKIs and identify splicing regulation of ATG16-L1 as a therapeutic vulnerability that could be explored for improving EGFR-targeted cancer therapy.</AbstractText>
          <CopyrightInformation>This article is protected by copyright. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Hatat</LastName>
            <ForeName>Anne-Sophie</ForeName>
            <Initials>AS</Initials>
            <AffiliationInfo>
              <Affiliation>Team "RNA splicing, cell signaling and response to therapies", Institute for Advanced Biosciences (IAB), INSERM U1209, CNRS UMR 5309, Grenoble Alpes University, Grenoble, France.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Benoit-Pilven</LastName>
            <ForeName>Clara</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>Laboratory of Biology and Modelling of the Cell, Univ Lyon, ENS de Lyon, Univ Claude Bernard, CNRS UMR 5239, INSERM U1210, 46 Allée d'Italie, Site Jacques Monod, F-69007, Lyon, France.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Pucciarelli</LastName>
            <ForeName>Amélie</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Team "RNA splicing, cell signaling and response to therapies", Institute for Advanced Biosciences (IAB), INSERM U1209, CNRS UMR 5309, Grenoble Alpes University, Grenoble, France.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>de Fraipont</LastName>
            <ForeName>Florence</ForeName>
            <Initials>F</Initials>
            <AffiliationInfo>
              <Affiliation>Team "RNA splicing, cell signaling and response to therapies", Institute for Advanced Biosciences (IAB), INSERM U1209, CNRS UMR 5309, Grenoble Alpes University, Grenoble, France.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Molecular Genetic Unit, Grenoble-Alpes University Hospital, Grenoble, France.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lamothe</LastName>
            <ForeName>Lucie</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Team "RNA splicing, cell signaling and response to therapies", Institute for Advanced Biosciences (IAB), INSERM U1209, CNRS UMR 5309, Grenoble Alpes University, Grenoble, France.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Perron</LastName>
            <ForeName>Pascal</ForeName>
            <Initials>P</Initials>
            <AffiliationInfo>
              <Affiliation>Team "RNA splicing, cell signaling and response to therapies", Institute for Advanced Biosciences (IAB), INSERM U1209, CNRS UMR 5309, Grenoble Alpes University, Grenoble, France.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Rey</LastName>
            <ForeName>Amandine</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Laboratory of Biology and Modelling of the Cell, Univ Lyon, ENS de Lyon, Univ Claude Bernard, CNRS UMR 5239, INSERM U1210, 46 Allée d'Italie, Site Jacques Monod, F-69007, Lyon, France.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Giaj Levra</LastName>
            <ForeName>Matteo</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Team "RNA splicing, cell signaling and response to therapies", Institute for Advanced Biosciences (IAB), INSERM U1209, CNRS UMR 5309, Grenoble Alpes University, Grenoble, France.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Thoracic Oncology Unit, Grenoble-Alpes University Hospital, Grenoble, France.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Toffart</LastName>
            <ForeName>Anne-Claire</ForeName>
            <Initials>AC</Initials>
            <AffiliationInfo>
              <Affiliation>Team "RNA splicing, cell signaling and response to therapies", Institute for Advanced Biosciences (IAB), INSERM U1209, CNRS UMR 5309, Grenoble Alpes University, Grenoble, France.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Thoracic Oncology Unit, Grenoble-Alpes University Hospital, Grenoble, France.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Auboeuf</LastName>
            <ForeName>Didier</ForeName>
            <Initials>D</Initials>
            <AffiliationInfo>
              <Affiliation>Laboratory of Biology and Modelling of the Cell, Univ Lyon, ENS de Lyon, Univ Claude Bernard, CNRS UMR 5239, INSERM U1210, 46 Allée d'Italie, Site Jacques Monod, F-69007, Lyon, France.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Eymin</LastName>
            <ForeName>Beatrice</ForeName>
            <Initials>B</Initials>
            <AffiliationInfo>
              <Affiliation>Team "RNA splicing, cell signaling and response to therapies", Institute for Advanced Biosciences (IAB), INSERM U1209, CNRS UMR 5309, Grenoble Alpes University, Grenoble, France.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Gazzeri</LastName>
            <ForeName>Sylvie</ForeName>
            <Initials>S</Initials>
            <Identifier Source="ORCID">0000-0001-5817-1839</Identifier>
            <AffiliationInfo>
              <Affiliation>Team "RNA splicing, cell signaling and response to therapies", Institute for Advanced Biosciences (IAB), INSERM U1209, CNRS UMR 5309, Grenoble Alpes University, Grenoble, France.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>05</Month>
          <Day>20</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Mol Oncol</MedlineTA>
        <NlmUniqueID>101308230</NlmUniqueID>
        <ISSNLinking>1574-7891</ISSNLinking>
      </MedlineJournalInfo>
      <CitationSubset>IM</CitationSubset>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">ATG16-L1</Keyword>
        <Keyword MajorTopicYN="N">Autophagy</Keyword>
        <Keyword MajorTopicYN="N">EGFR-TKI</Keyword>
        <Keyword MajorTopicYN="N">Non-small-cell lung cancer</Keyword>
        <Keyword MajorTopicYN="N">resistance</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="revised">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>25</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>11</Month>
          <Day>18</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>6</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>20</Day>
          <Hour>4</Hour>
          <Minute>24</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>21</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>21</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>aheadofprint</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35593080</ArticleId>
        <ArticleId IdType="doi">10.1002/1878-0261.13229</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
